Mutazioni del gene APOC3, metabolismo dei trigliceridi e riduzione di eventi ischemici cardiovascolari

Translated title of the contribution: Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events

Angela Pirillo, Alberico Luigi Catapano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A direct relationship between high plasma triglyceride (TG) levels and increased risk of cardiovascular disease has been shown in several studies. TG are present in the blood associated with different lipoprotein classes, including hepatically-derived very low density lipoproteins (VLDL) and intestinally-derived chylomicrons. Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes TG, releasing free fatty acids that accumulate in peripheral tissues and remnant lipoproteins, that are then cleared by the liver. LPL activity is finely modulated by several cofactors, including apolipoprotein C-III (apoC-III) which acts as a LPL inhibitor. The key role of apoC-III has been established in several studies: animal models lacking APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 gene led to increased TG levels. In humans, several mutations in APOC3 gene have been identified, leading to lower apoC-III levels and associated with reduced plasma TG levels. Recently, these mutations were found to be associated with a reduced risk for cardiovascular ischemia and coronary heart disease, thus confirming the negative role of apoC-III in TG metabolism and suggesting apoC-III as possible therapeutic target for the management of hypertriglyceridemia.

Original languageItalian
Pages (from-to)289-294
Number of pages6
JournalGiornale Italiano di Cardiologia
Volume16
Issue number5
Publication statusPublished - May 1 2015

Fingerprint

Apolipoprotein C-III
Triglycerides
Mutation
Lipoprotein Lipase
Genes
Lipoproteins
Chylomicrons
VLDL Lipoproteins
Hypertriglyceridemia
Nonesterified Fatty Acids
Coronary Disease
Cardiovascular Diseases
Ischemia
Animal Models
Liver
Enzymes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Mutazioni del gene APOC3, metabolismo dei trigliceridi e riduzione di eventi ischemici cardiovascolari. / Pirillo, Angela; Catapano, Alberico Luigi.

In: Giornale Italiano di Cardiologia, Vol. 16, No. 5, 01.05.2015, p. 289-294.

Research output: Contribution to journalArticle

@article{5752a7e1b9c044e193f40f6327d233af,
title = "Mutazioni del gene APOC3, metabolismo dei trigliceridi e riduzione di eventi ischemici cardiovascolari",
abstract = "A direct relationship between high plasma triglyceride (TG) levels and increased risk of cardiovascular disease has been shown in several studies. TG are present in the blood associated with different lipoprotein classes, including hepatically-derived very low density lipoproteins (VLDL) and intestinally-derived chylomicrons. Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes TG, releasing free fatty acids that accumulate in peripheral tissues and remnant lipoproteins, that are then cleared by the liver. LPL activity is finely modulated by several cofactors, including apolipoprotein C-III (apoC-III) which acts as a LPL inhibitor. The key role of apoC-III has been established in several studies: animal models lacking APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 gene led to increased TG levels. In humans, several mutations in APOC3 gene have been identified, leading to lower apoC-III levels and associated with reduced plasma TG levels. Recently, these mutations were found to be associated with a reduced risk for cardiovascular ischemia and coronary heart disease, thus confirming the negative role of apoC-III in TG metabolism and suggesting apoC-III as possible therapeutic target for the management of hypertriglyceridemia.",
author = "Angela Pirillo and Catapano, {Alberico Luigi}",
year = "2015",
month = "5",
day = "1",
language = "Italian",
volume = "16",
pages = "289--294",
journal = "Giornale Italiano di Cardiologia",
issn = "1827-6806",
publisher = "CEPI s.r.l.",
number = "5",

}

TY - JOUR

T1 - Mutazioni del gene APOC3, metabolismo dei trigliceridi e riduzione di eventi ischemici cardiovascolari

AU - Pirillo, Angela

AU - Catapano, Alberico Luigi

PY - 2015/5/1

Y1 - 2015/5/1

N2 - A direct relationship between high plasma triglyceride (TG) levels and increased risk of cardiovascular disease has been shown in several studies. TG are present in the blood associated with different lipoprotein classes, including hepatically-derived very low density lipoproteins (VLDL) and intestinally-derived chylomicrons. Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes TG, releasing free fatty acids that accumulate in peripheral tissues and remnant lipoproteins, that are then cleared by the liver. LPL activity is finely modulated by several cofactors, including apolipoprotein C-III (apoC-III) which acts as a LPL inhibitor. The key role of apoC-III has been established in several studies: animal models lacking APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 gene led to increased TG levels. In humans, several mutations in APOC3 gene have been identified, leading to lower apoC-III levels and associated with reduced plasma TG levels. Recently, these mutations were found to be associated with a reduced risk for cardiovascular ischemia and coronary heart disease, thus confirming the negative role of apoC-III in TG metabolism and suggesting apoC-III as possible therapeutic target for the management of hypertriglyceridemia.

AB - A direct relationship between high plasma triglyceride (TG) levels and increased risk of cardiovascular disease has been shown in several studies. TG are present in the blood associated with different lipoprotein classes, including hepatically-derived very low density lipoproteins (VLDL) and intestinally-derived chylomicrons. Lipoprotein lipase (LPL) is a key enzyme that hydrolyzes TG, releasing free fatty acids that accumulate in peripheral tissues and remnant lipoproteins, that are then cleared by the liver. LPL activity is finely modulated by several cofactors, including apolipoprotein C-III (apoC-III) which acts as a LPL inhibitor. The key role of apoC-III has been established in several studies: animal models lacking APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 gene led to increased TG levels. In humans, several mutations in APOC3 gene have been identified, leading to lower apoC-III levels and associated with reduced plasma TG levels. Recently, these mutations were found to be associated with a reduced risk for cardiovascular ischemia and coronary heart disease, thus confirming the negative role of apoC-III in TG metabolism and suggesting apoC-III as possible therapeutic target for the management of hypertriglyceridemia.

UR - http://www.scopus.com/inward/record.url?scp=84936751952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936751952&partnerID=8YFLogxK

M3 - Articolo

VL - 16

SP - 289

EP - 294

JO - Giornale Italiano di Cardiologia

JF - Giornale Italiano di Cardiologia

SN - 1827-6806

IS - 5

ER -